PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer - OncLive

William Oh, MD

William Oh, MD

The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
... to read the full story


Comments

Popular posts from this blog

Q&A

Sentinel lymph node biopsy: What cancer patients should know

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...